CoLucid Pharmaceuticals has raised $7.5 million of a planned $9.5 million financing to support the central nervous system drug development company’s late-stage development of its novel migraine headache treatment. Participating in the convertible note financing were existing investors Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. Durham, North Carolina-based […]
Research Triangle Park-based CoLucid Pharmaceuticals raised another $1.5 million recently to bring its latest round of fundraising to $3.5 million, according to a Tuesday filing with the Securities and Exchange Commission. The drug development company could raise up to $9.5 million, according to the filing. But the company says it wants to raise $6.5 million […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
A new migraine treatment from CoLucid Pharmaceuticals is approaching phase 3 clinical trials and the North Carolina-based company is raising $6.5 million in a bridge round of financing to get it there.